CompletedPhase 1NCT01921426

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

Studying Squamous cell carcinoma of the oral cavity

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Galera Therapeutics, Inc.
Principal Investigator
Jon T. Holmlund, MD, MD
Galera Therapeutics, Inc.
Intervention
GC4419(drug)
Enrollment
30 target
Eligibility
18 years · All sexes
Timeline
20132016

Study locations (10)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01921426 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of the oral cavity

Additional recruiting or active studies for the same condition.

See all trials for Squamous cell carcinoma of the oral cavity

← Back to all trials